Cerulean Pharma to Present at JMP Securities Healthcare Conference

CAMBRIDGE, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced that Christopher D. T. Guiffre, J.D., Senior Vice President and Chief Business Officer, will present at the JMP Securities Healthcare Conference in New York City on Tuesday, June 24, 2014, at 3:30 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.ceruleanrx.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanopharmaceuticals designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with approved cancer treatments with the aim of unlocking the power of combination therapy. www.ceruleanrx.com

CONTACT: For IR:
         Heather Savelle
         MacDougall Biomedical Communications
         781.235.3060
         [email protected]

         For PR:
         Laura Kempke
         MSLGROUP
         781.684.0770
         [email protected]

You May Also Be Interested In

• NTC Thermistors are the Small Sensors Behind Smarter Industrial Growth
• Golden Body Scrub Combines Triple Salt Blend with 1000mg CBD
• HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)